Tata 1mg Unicorn Investor Acquired

Mission to make healthcare 'understandable, accessible and affordable,' addressing a prior gap where health information in India was unavailable or incomprehensible.

First Indian healthcare platform to earn LegitScript certification and ISO/IEC 27001:2022 certified for information security; free online doctor consultations and home sample collection.

Consumers across 1,800+ Indian cities buying prescription/OTC medicines, booking lab tests, and seeking online doctor consultations.

Tata 1mg partners with corporates (via brokers such as Mahindra Insurance Brokers) to offer employee wellness programmes — 24x7 tele-doctor access, 1-1 counselling, and home sample collection — and partners with insurers for integrated digital healthcare benefits.

Strategic partnership designing customized wellness packages for corporates/employees/families: 24x7 tele-doctor access, 1-1 counselling, home sample collection, discounts on pharmacy and health check-ups.

Paid membership tier (monthly/quarterly/half-yearly) giving individual consumers dedicated assistance and self-service perks: unlimited free doctor e-consultations across 26+ specialities, free home sample collection, priority order/prescription processing, and dedicated customer-support agents.

Self-service loyalty layer stacked on top of individual orders: 1mg Cash reward points earned via coupon codes and redeemable on future purchases, plus a co-branded tie-up letting Air India Maharaja Club / Tata Neu members earn airline miles on medicine, lab-test and wellness purchases.

In-app notification system that reminds consumers to take medicines on schedule and auto-triggers prescription refill orders for chronic-illness patients, turning one-time buyers into recurring customers with minimal manual effort.

Primary digital storefront serving 1,800+ cities with 260M+ site visitors and 31M+ orders delivered.

Expanded to 280+ physical stores across nine clusters as of FY26, with plans to grow to 500+ outlets within 12 months.

30-60 minute express medicine delivery live across 10 cities.

Partnership with ClickPost applies AI-powered Performance-Based Courier Allocation and route optimization across Tata 1mg's medicine delivery network to cut delivery times.

Running sample collection and lab-test processing at scale, including opening its first company-owned reference diagnostics lab in Delhi to bring more testing in-house and improve turnaround/quality control.

Operating video/audio/chat consultations with registered doctors across specialties, issuing valid e-prescriptions and offering free follow-ups, directly feeding the pharmacy order pipeline.

Developing and operating consumer-facing AI tools like the Health Insights Hub and 'Ask a Doctor' chatbot, while also running the Pulse platform as an ongoing analytics service sold to pharmaceutical companies.

In-house built Order Delivery Intelligent Network gives Tata 1mg real-time visibility across purchase, inwarding, picking, quality checks, packaging, shipping, tracking and inventory for its pharmacy fulfillment operations pan-India.

A network of company-owned diagnostic labs (including a national reference lab in Delhi) plus verified partner labs across major metros gives Tata 1mg the physical testing capacity behind its e-diagnostics business.

A proprietary AI-powered analytics platform that turns Tata 1mg's consumer health and prescription data into insights product, now sold as a B2B offering to pharmaceutical companies.

A compliance-driven workforce of licensed pharmacists for dispensing plus a network of registered doctors (via a dedicated doctor-side app) underpins both the retail pharmacy and teleconsultation lines of business.

Strategic partnership for corporate wellness solutions.

March 2022 strategic investment (undisclosed sum) in radiology/digital diagnostics startup 5C Network to strengthen diagnostic capabilities.

May 2025 partnership integrating Unicommerce's SaaS technology to automate multi-channel order management and warehouse operations across 1,000+ Indian cities.

Margin on medicine MRP; ePharmacy business reached breakeven in FY26.

Diagnostics business crossed ₹600 crore in annual recurring revenue (ARR) with 40%+ YoY growth in FY26; historically diagnostics accounted for a large share of revenue.

Specialty Pharma division grew ~65% in FY26, driven by patient support programmes, adult vaccination, cancer care and obesity management.

1mg Care Plan subscription for ongoing health management.

Cost of procuring medicines and pharma products for resale to fulfill 31M+ delivered orders is Tata 1mg's single largest expense line, ahead of employee costs, logistics, and marketing combined.

Salaries, wages and benefits for pharmacists, doctors, delivery/logistics staff, lab technicians and corporate teams across the pharmacy, diagnostics and teleconsultation businesses.

Capital and operating spend on a growing network of NABL-accredited owned diagnostic labs plus a CAP-accredited National Reference Lab in Delhi, alongside payouts to partner labs, underpins the e-diagnostics business.

Capex to fit out new offline pharmacy/wellness stores plus ongoing rent, staffing and compliance opex as Tata 1mg scales its omnichannel retail footprint alongside its online business.